Skip to main content
Erschienen in: Strahlentherapie und Onkologie 1/2022

02.09.2021 | Original Article

Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma—a real-world, population-based study

verfasst von: Dr. Omar Abdel-Rahman

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess the impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma in a real-world setting.

Methods

The Surveillance, Epidemiology, and End Results Research Plus database was accessed, and patients with resected non-metastatic adrenocortical carcinoma diagnosed 2010–2015 were reviewed. Kaplan–Meier estimates and log-rank testing were used to examine the impact of postoperative radiotherapy on overall and cancer-specific survival. Multivariable Cox regression analysis was used to explore factors associated with overall and cancer-specific survival.

Results

A total of 294 patients were included in the final analysis, including 60 patients (20.4%) who received postoperative radiotherapy. Using Kaplan–Meier estimates, individuals who received postoperative radiotherapy have better overall survival (P = 0.002). Multivariable cox regression analysis showed that the following factors were associated with worse overall survival: older age (HR: 1.01; 95% CI: 1.00–1.03), male sex (HR for female sex versus male sex: 0.61; 95% CI: 0.43–0.85), and non-receipt of postoperative radiation therapy (HR: 2.29; 95% CI: 1.38–3.77). Systemic therapy was not associated with differences in overall survival (HR: 0.77; 95% CI: 0.54–1.10). Likewise, the following factors were associated with worse cancer-specific survival: male sex (HR for female sex versus male sex: 0.60; 95% CI: 0.41–0.88), non-receipt of postoperative radiation therapy (HR: 2.17; 95% CI: 1.27–3.70), and receipt of perioperative systemic therapy (HR: 0.67; 95% CI: 0.45–0.99).

Conclusion

Postoperative radiotherapy following resection of adrenocortical carcinoma is associated with better overall and cancer-specific survival.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Crona J, Baudin E, Terzolo M, Chrisoulidou A, Angelousi A, Ronchi CL et al (2021) ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. Eur J Endocrinol 184(2):R51–R59CrossRef Crona J, Baudin E, Terzolo M, Chrisoulidou A, Angelousi A, Ronchi CL et al (2021) ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. Eur J Endocrinol 184(2):R51–R59CrossRef
3.
Zurück zum Zitat Buller DM, Hennessey AM, Ristau BT (2021) Open versus minimally invasive surgery for suspected adrenocortical carcinoma. Transl Androl Urol 10(5):2246–2263CrossRef Buller DM, Hennessey AM, Ristau BT (2021) Open versus minimally invasive surgery for suspected adrenocortical carcinoma. Transl Androl Urol 10(5):2246–2263CrossRef
4.
Zurück zum Zitat Bedrose S, Daher M, Altameemi L, Habra MA (2020) Adjuvant therapy in adrenocortical carcinoma: reflections and future directions. Cancers (Basel) 12(2):508CrossRef Bedrose S, Daher M, Altameemi L, Habra MA (2020) Adjuvant therapy in adrenocortical carcinoma: reflections and future directions. Cancers (Basel) 12(2):508CrossRef
5.
Zurück zum Zitat Kostiainen I, Hakaste L, Kejo P, Parviainen H, Laine T, Löyttyniemi E et al (2019) Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine 65(1):166–174CrossRef Kostiainen I, Hakaste L, Kejo P, Parviainen H, Laine T, Löyttyniemi E et al (2019) Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. Endocrine 65(1):166–174CrossRef
6.
Zurück zum Zitat Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F et al (2021) What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question. J Pers Med 11(4):269CrossRef Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F et al (2021) What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question. J Pers Med 11(4):269CrossRef
7.
Zurück zum Zitat Abdel-Rahman O (2018) Impact of regional nodal irradiation on the outcomes of N1 breast cancer patients referred for adjuvant treatment: a patient-level pooled analysis of 2 clinical trials. Clin Breast Cancer 18(6):504–510CrossRef Abdel-Rahman O (2018) Impact of regional nodal irradiation on the outcomes of N1 breast cancer patients referred for adjuvant treatment: a patient-level pooled analysis of 2 clinical trials. Clin Breast Cancer 18(6):504–510CrossRef
8.
Zurück zum Zitat Abdel-Rahman O, Elhalawani HM, Allen PK, Holliday EB (2018) Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States. Adv Radiat Oncol 3(4):611–620CrossRef Abdel-Rahman O, Elhalawani HM, Allen PK, Holliday EB (2018) Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States. Adv Radiat Oncol 3(4):611–620CrossRef
9.
Zurück zum Zitat Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D et al (2018) NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 16(6):693–702CrossRef Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D et al (2018) NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 16(6):693–702CrossRef
10.
Zurück zum Zitat Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1476–1490CrossRef Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1476–1490CrossRef
11.
Zurück zum Zitat Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R et al (2018) European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179(4):G1–G46CrossRef Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R et al (2018) European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179(4):G1–G46CrossRef
12.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (2020) SEER*Stat database: incidence—SEER research plus data, 18 registries, Nov 2019 sub (2000–2017)—linked to county attributes—total U.S., 1969–2018 counties, National Cancer Institute, DCCPS, surveillance research program. www.seer.cancer.gov (based on the November 2019 submission). Accessed: 31. March 2021 Surveillance, Epidemiology, and End Results (SEER) Program (2020) SEER*Stat database: incidence—SEER research plus data, 18 registries, Nov 2019 sub (2000–2017)—linked to county attributes—total U.S., 1969–2018 counties, National Cancer Institute, DCCPS, surveillance research program. www.​seer.​cancer.​gov (based on the November 2019 submission). Accessed: 31. March 2021
13.
Zurück zum Zitat Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356(23):2372–2380CrossRef Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356(23):2372–2380CrossRef
15.
Zurück zum Zitat Abdel-Rahman O (2018) Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 168(1):269–275CrossRef Abdel-Rahman O (2018) Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 168(1):269–275CrossRef
16.
Zurück zum Zitat Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JEM et al (2020) Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 30(6):871–877CrossRef Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JEM et al (2020) Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 30(6):871–877CrossRef
17.
Zurück zum Zitat Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS et al (2015) Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 92(2):252–259CrossRef Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS et al (2015) Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 92(2):252–259CrossRef
18.
Zurück zum Zitat Zhu J, Zheng Z, Shen J, Lian X, Miao Z, Shen J et al (2020) Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiat Oncol 15(1):118CrossRef Zhu J, Zheng Z, Shen J, Lian X, Miao Z, Shen J et al (2020) Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiat Oncol 15(1):118CrossRef
Metadaten
Titel
Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma—a real-world, population-based study
verfasst von
Dr. Omar Abdel-Rahman
Publikationsdatum
02.09.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 1/2022
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-021-01838-6

Weitere Artikel der Ausgabe 1/2022

Strahlentherapie und Onkologie 1/2022 Zur Ausgabe

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.